Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25164661 | 0.81 | PPARD (0.37) | CYP1A2HRH2HRH1HRH4 | |
| SCHEMBL13306767 | 0.78 | ALDH1A1 (0.31) | CYP1A2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL22966526 | 0.72 | SIGMAR1 (0.37) | CNR1CNR2HRH1 | |
| SCHEMBL10220328 | 0.72 | NOS1 (0.44) | CNR1CNR2KMT2A | |
| SCHEMBL755570 | 0.72 | — | — | |
| SCHEMBL22966583 | 0.71 | TSHR (0.38) | HRH1SMN1; SMN2 | |
| SCHEMBL22966581 | 0.71 | GSR (0.37) | CNR1CNR2KMT2AMEN1 | |
| SCHEMBL10227000 | 0.70 | KMT2A (0.54) | CNR1CNR2KMT2A | |
| SCHEMBL12806717 | 0.70 | — | — | |
| SCHEMBL15796727 | 0.70 | COMT (0.42) | CYP1A2HRH2HRH1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115849-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115849-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | CNR1 925/4885CNR2 683/4885CYP1A2 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.